News

News

01-10

2025

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

12-12

2024

Sciwind’s Second Marketing Authorization Application of Ecnoglutide for Chronic Weight Management Has Been Accepted by the NMPA of China

11-24

2024

Marketing Authorization Application for Ecnoglutide, a First-in-Class Biased GLP-1 Peptide Agonist, has Been Accepted by the NMPA of China

05-07

2024

Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea

01-23

2024

Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide

01-02

2024

Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China

<
1
2
3
4
5
>